Inhaled cyclosporine - A breath of fresh air?

New England Journal of Medicine

Volumn 354, Issue 2, 2006, Pages 191-193

  DeCamp Jr , Malcolm M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

BIOPSY; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DEATH; DONOR SELECTION; EDITORIAL; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LUNG DISEASE; LUNG TRANSPLANTATION; MAINTENANCE THERAPY; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; SURGICAL MORTALITY; SURGICAL PATIENT; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT PLANNING;

ADMINISTRATION, INHALATION; CHRONIC DISEASE; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; SURVIVAL ANALYSIS;

EID: 30444460597     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe058287     Document Type: Editorial

References (11)

1. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report - 2005. J Heart Lung Transplant 2005;24:956-67.
2. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999;116:127-33.
3. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005;130:528-37.
4. Barr ML, Bourge RC, Orens JB, et al. Thoracic organ transplantation in the United States, 1994-2003. Am J Transplant 2005;5:934-49.
5. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4-14.
6. Scott AI, Sharples LD, Stewart S. Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies. Drugs 2005;65:761-71.
7. Date H, Lynch JP, Sundaresan S, Patterson GA, Trulock EP. The impact of cytolytic therapy on bronchiolitis obliterans syndrome. J Heart Lung Transplant 1998;17:869-75.
8. Iacono AT, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006;354:141-50.
9. Zhang JH, Dong ZJ, Zhou RB, Luo de M, Wei HM, Tian ZG. Isolation of lymphocytes and their innate immune characterizations from liver, intestine, lung and uterus. Cell Mol Immunol 2005;2:271-80.
10. Sester U, Gartner BC, Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005;5:1483-9.
11. Whitford H, Walters EH, Levvey B, et al. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation 2002;73:1793-9.